Cryoport (CYRX) to Release Quarterly Earnings on Thursday

Cryoport (NASDAQ:CYRX) will be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect Cryoport to post earnings of ($0.29) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($0.37) by ($1.25). The business had revenue of $57.60 million for the quarter, compared to analysts’ expectations of $57.65 million. Cryoport had a negative return on equity of 15.55% and a negative net margin of 76.48%. The company’s revenue was up 1.0% compared to the same quarter last year. During the same period last year, the business posted ($0.42) earnings per share. On average, analysts expect Cryoport to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cryoport Trading Up 2.9 %

NASDAQ:CYRX traded up $0.22 during mid-day trading on Tuesday, reaching $7.89. 87,985 shares of the company’s stock traded hands, compared to its average volume of 567,691. The company has a debt-to-equity ratio of 0.97, a current ratio of 8.38 and a quick ratio of 7.99. Cryoport has a 12-month low of $5.32 and a 12-month high of $20.10. The firm has a market capitalization of $389.86 million, a price-to-earnings ratio of -2.09 and a beta of 1.63. The company has a 50 day moving average price of $7.81 and a 200-day moving average price of $9.44.

Cryoport declared that its Board of Directors has authorized a share buyback program on Tuesday, August 6th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to reacquire up to 49.1% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. UBS Group lifted their price objective on Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, October 18th. Jefferies Financial Group lowered Cryoport from a “buy” rating to a “hold” rating and reduced their target price for the stock from $20.00 to $8.00 in a research note on Wednesday, August 7th. B. Riley upgraded shares of Cryoport from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $19.00 to $15.00 in a report on Wednesday, July 31st. Finally, Needham & Company LLC decreased their target price on shares of Cryoport from $18.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.